Get to know our people and story
About DoseVue
DoseVue History
DoseVue was founded in 2013 as the first spin-off of the Belgian Nuclear Research Center (SCK•CEN), an internationally renowned player in the field of radiation protection and dosimetry research. Together with academic and industry partners (including SIT and Eckert Ziegler), we are continually expanding our product portfolio of in-vivo dosimetry solutions. With the dedicated support of our investors Innovation Fund and LRM, DoseVue is led by an experienced management team and board of directors.
Executive team
Nicolas Geûens is a life sciences entrepreneur with over 20 years international general management, commercial and market access experience in small and large organizations. Before joining DoseVue as CEO, Nicolas co-founded Convert Pharmaceuticals and led the commercial launches in Europe of Endo Tools Therapeutics and PneumRx (acquired by BTG). Previously, Nicolas held various national and international leadership positions at Johnson & Johnson. Nicolas is an adviser to NLC Ventures, the European Healthtech venture builder. He earned a master’s degree in business from the Solvay and Vlerick management schools and an MBA from the Wharton School of the University of Pennsylvania.
Emiliano D’Agostino is co-founder and CTO of DoseVue. Previously, Emiliano worked for several years at the Belgian Nuclear Research Center within the dosimetry group. Over the years, Emiliano has developed extensive expertise in the design and characterization of new dosimeters, particularly in luminescence-based devices. Emiliano holds a MSc in nuclear engineering from the Politecnico di Milano and a second MSc in physics engineering from the Free University Brussels (ULB). He obtained a PhD in biomedical/electrical engineering from the University of Leuven.
Adrian Plesu helped to develop the DoseVue product range and is currently responsible for production and product management. Prior to joining DoseVue in 2017, Adrian worked at the Centre Antoine Lacassagne as a medical dosimetrist, where he acquired an extensive experience in medical physics and radioprotection. Previously, he worked as lead designer in an advertising agency he co-founded. Adrian holds university degrees in physics, dosimetry and radioprotection from Alexandru Ioan Cuza University and Université Côte d'Azur.
Andrea Giammanco is currently responsible for the training and on-site support of customers. In his previous role, Andrea managed the production and maintenance of R&D documentation in the Quality Management System. Moreover, Andrea is responsible for work packages with the European project “AMPHORA” that aims at developing acoustic markers for enhanced remote sensing of radiation doses. Over the years, Andrea has developed extensive expertise in the use of Monte Carlo codes also for the characterization and simulation of radiation detectors. He holds a M.Sc in Nuclear Engineering from both Politecnico di Milano and Politecnico di Torino and master’s thesis at the KU Leuven.
Madalina Cociorb joined DoseVue in 2018 as a project manager for R&D and production activities and supported the implementation of the Quality Management System. In addition to her responsibilities at DoseVue, Madalina is currently pursuing a PhD in Chemistry. In her doctoral research, Madalina is investigating the development of new scintillator materials for dosimetry application in collaboration with the Tor Vergata University of Rome. In 2018, she obtained a MSc in Chemistry from the Tor Vergata University of Rome as part of the European project “AMPHORA” where she developed phase-change ultrasound contrast agents as dosimetry systems.
Scientific Advisors
Dirk Verellen, PhD
Dr. Dirk Verellen is a Professor at Antwerp University and Head of Medical Physics at the Iridium Cancer Network Antwerp. Dr. Verellen received his Ph.D. in medical sciences from the VUB and is the author of over 150 peer-reviewed scientific papers, editor or contributing author of several books, and has served in the board of editors for multiple scientific journals. At the European Society for Radiotherapy and Oncology (ESTRO), he serves as treasurer and member of the Board of Directors in the Physics Committee and the Radiation Oncology Safety Committee, and is a course director at the ESTRO School of Radiotherapy and Oncology. Dr. Verellen’s main interests include practical implementation of conformal radiotherapy and image-guidance in a clinical environment, and safety and quality management in radiotherapy.
Dr. Charles Scarantino
Dr. Charles Scarantino is a radiation oncologist affiliated with the University of North Carolina at Chapel Hill, NC as Emeritus Faculty. Dr. Scarantino has been in clinical practice for over three decades and has over forty publications in clinical and basic cell research. He completed a PhD in Cell Physiology at St. John’s University, Medical Degree from Bowman Gray School of Medicine of Wake Forest University, Residency and Fellowship training in Radiation Oncology at the University of Rochester. In addition to his clinical practice, he has focused on applying basic research techniques to predict response to oncotherapy and has co-founded two startup companies in this field: Sicel Technology and Lucerno Dynamics.
Board of Directors
Staf Van Reet
Chairman of the board, Senior Executive
Dr. Staf Van Reet is the Managing Director of VIZIPhar Biosciences. Staf was formerly active as Managing Director of Janssen Pharmaceutica, Head of R&D of the Janssen Group and a member of the Group Operating Committee of the pharmaceutical sector of Johnson & Johnson. From 2000 – 2004, Staf was Vice President of the Johnson & Johnson Development Corporation, the venture capital arm of Johnson & Johnson. He was a co-founder and Chairman of the Board of Directors of Movetis until the company was acquired by Shire Holdings in 2010. Currently, Staf is Chairman of the Board of Directors of Thrombogenics, Actogenix and the Flemish Institute for Biotechnology (VIB) and a Director of Biocartis and Therasolve. Staf obtained his Master and PhD in Bio-engineering Sciences from KU Leuven.
Dries Evers
Investment Manager, LRM
Christian Legrain
Vice President, European Nuclear Society
Hildegarde Vandenhove
Director Environment Health and Safety, Belgian Nuclear Research Centre (SCK-CEN)
André Ostachkov
Principal, The Innovation Fund
Partners
